Trial Profile

A Phase I Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fostamatinib (Primary)
Indications Sickle cell anaemia
Focus Adverse reactions

Most Recent Events

15 Sep 2025 Planned primary completion date changed from 31 Aug 2025 to 14 May 2026.
22 Jan 2025 According to the Rigel Pharmaceuticals Media Release, first patient has been enrolled in this study.
20 Dec 2024 Planned initiation date changed from 25 Dec 2024 to 26 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com